Cargando…

Targeting Human Herpesviruses: An Effective Strategy for Treating Idiopathic Pulmonary Fibrosis?

Detalles Bibliográficos
Autor principal:	Maher, Toby M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2021
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513649/ https://www.ncbi.nlm.nih.gov/pubmed/34328404 http://dx.doi.org/10.1513/AnnalsATS.202105-536ED

Ejemplares similares

Small Airways in Idiopathic Pulmonary Fibrosis: Quiet but Not Forgotten
por: Maher, Toby M.
Publicado: (2021)

Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Call to Arms
por: Kreuter, Michael, et al.
Publicado: (2020)

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
por: Maher, Toby M., et al.
Publicado: (2019)

Biomarkers for Interstitial Lung Abnormalities: A Stepping-stone Toward Idiopathic Pulmonary Fibrosis Prevention?
por: Maher, Toby M.
Publicado: (2022)

No association between human herpesvirus or herpesvirus saimiri and idiopathic pulmonary fibrosis
por: Le Hingrat, Quentin, et al.
Publicado: (2020)

The treatment of idiopathic pulmonary fibrosis
por: Woodcock, Hannah V., et al.
Publicado: (2014)

Recent advances in understanding idiopathic pulmonary fibrosis
por: Daccord, Cécile, et al.
Publicado: (2016)

Epstein-Barr Virus and Human Herpesvirus 8 in Idiopathic Pulmonary Fibrosis
por: Jafarian, Amir Hossein, et al.
Publicado: (2020)

Current and novel drug therapies for idiopathic pulmonary fibrosis
por: Adamali, Huzaifa I, et al.
Publicado: (2012)

Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK
por: Strongman, Helen, et al.
Publicado: (2018)

On Target: CYFRA 21-1 as an Idiopathic Pulmonary Fibrosis Biomarker
por: Spagnolo, Paolo, et al.
Publicado: (2022)

Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis
por: Kolb, Martin, et al.
Publicado: (2023)

Idiopathic pulmonary fibrosis is strongly associated with productive infection by herpesvirus saimiri
por: Folcik, Virginia A, et al.
Publicado: (2014)

Global incidence and prevalence of idiopathic pulmonary fibrosis
por: Maher, Toby M., et al.
Publicado: (2021)

Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent, et al.
Publicado: (2015)

Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use
por: Diamantopoulos, Alex, et al.
Publicado: (2018)

Idiopathic pulmonary fibrosis: moving forward
por: Richeldi, Luca
Publicado: (2015)

State of the Art in Idiopathic Pulmonary Fibrosis
por: El Agha, Elie, et al.
Publicado: (2022)

Mendelian randomization reveals no correlations between herpesvirus infection and idiopathic pulmonary fibrosis
por: Yan, Haihao, et al.
Publicado: (2023)

Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
por: Kreuter, Michael, et al.
Publicado: (2017)

Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib
por: Woodcock, Hannah V, et al.
Publicado: (2013)

Autophagy in Idiopathic Pulmonary Fibrosis: Predisposition of the Aging Lung to Fibrosis?
por: Zmijewski, Jaroslaw W., et al.
Publicado: (2022)

B Cells in Idiopathic Pulmonary Fibrosis: Targeting Immune Cells with Antifibrotic Agents
por: Roman, Jesse, et al.
Publicado: (2021)

The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review
por: Diamantopoulos, Alex, et al.
Publicado: (2018)

Toward Early Detection of Idiopathic Pulmonary Fibrosis
por: Schupp, Jonas Christian, et al.
Publicado: (2019)

Idiopathic pulmonary fibrosis management: caring is sparing
por: Nava, Stefano, et al.
Publicado: (2020)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

ATP12A: Connecting Mucus and Fibrosis in Idiopathic Pulmonary Fibrosis
por: Zabner, Joseph, et al.
Publicado: (2023)

Molecular pathways in idiopathic pulmonary fibrosis pathogenesis: Transcending barriers to optimally targeted pharmacotherapies
por: Strykowski, Rachel, et al.
Publicado: (2021)

Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives
por: Kreuter, Michael, et al.
Publicado: (2015)

Guidelines or guidance for better idiopathic pulmonary fibrosis management?
por: Behr, Jürgen
Publicado: (2016)

Ironing Out the Roles of Macrophages in Idiopathic Pulmonary Fibrosis
por: O’Dwyer, David N., et al.
Publicado: (2019)

Another Weapon in the Battle against Idiopathic Pulmonary Fibrosis?
por: Wilson, Carole L., et al.
Publicado: (2019)

Idiopathic pulmonary fibrosis: accurate diagnosis and early treatment
por: Morais, António
Publicado: (2019)

Chronic Cough in Idiopathic Pulmonary Fibrosis: The Same Difference?
por: Morice, Alyn H.
Publicado: (2022)

The Role of the Lung’s Microbiome in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis
por: Spagnolo, Paolo, et al.
Publicado: (2019)

Idiopathic pulmonary fibrosis: a paradigm of late-onset, single-gene human disease?
por: Chapman, Stephen J, et al.
Publicado: (2014)

Circulating fibrocytes are not disease-specific prognosticators in idiopathic pulmonary fibrosis
por: Stewart, Iain D., et al.
Publicado: (2021)

Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis
por: Ma, Hongbo, et al.
Publicado: (2022)

Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis
por: Kreuter, Michael, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_84h9jkdcslc4dbmilnbe0me3oo